Literature DB >> 7273792

Analysis of survival data with nonproportional hazard functions.

D M Stablein, W H Carter, J W Novak.   

Abstract

The log-rank test or the proportional hazard model is a valuable, widely accepted method for analyzing time-to-response data from comparative clinical trials. When the hazard ratio is constant in time, this procedure is optimal. Indiscriminate or unthinking use of this approach results in problems in the determination of treatment differences. For example, when the true survival curves intersect, the hazard ratio cannot be constant, i.e., the hazard functions are not proportional. It is shown that by considering time-by-treatment interactions we gain flexibility in describing the relationships among hazard functions. In this paper we demonstrate with the results of a clinical trial how available methodology can be used to permit tests for the appropriateness of the model and to enable informative analysis of such data.

Mesh:

Year:  1981        PMID: 7273792     DOI: 10.1016/0197-2456(81)90005-2

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  4 in total

1.  Checking the censored two-sample accelerated life model using integrated cumulative hazard difference.

Authors:  Seung-Hwan Lee; Song Yang
Journal:  Lifetime Data Anal       Date:  2007-05-26       Impact factor: 1.588

2.  Neural Survival Clustering: Non-parametric mixture of neural networks for survival clustering.

Authors:  Vincent Jeanselme; Brian Tom; Jessica Barrett
Journal:  Proc Mach Learn Res       Date:  2022

3.  EMPIRICAL LIKELIHOOD INFERENCE FOR THE COX MODEL WITH TIME-DEPENDENT COEFFICIENTS VIA LOCAL PARTIAL LIKELIHOOD.

Authors:  Yanqing Sun; Rajeshwari Sundaram; Yichuan Zhao
Journal:  Ann Stat       Date:  2009-09-01       Impact factor: 4.028

4.  Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.

Authors:  Eliana Rulli; Francesca Ghilotti; Elena Biagioli; Luca Porcu; Mirko Marabese; Maurizio D'Incalci; Rino Bellocco; Valter Torri
Journal:  Br J Cancer       Date:  2018-11-13       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.